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THE ROLE OF GABA-B IN SENSORIMOTOR GATING PROCESSING 
DISORDERS IN RAT MODELS, AN AUTORADIOGRAPHIC STUDY 
ALEX ZHUANG 
ABSTRACT 
Introduction: The process of sensorimotor gating is a neurological phenomenon 
referring to the brain’s ability to process and filter out stimuli in order to prevent an 
overflow of information. This phenomenon can be operationally measured by prepulse 
inhibition, which is the attenuation of a stimulus-induced startle response by introducing 
a milder preceding stimulus. Studies have shown that impairment of prepulse inhibition 
(PPI) has been correlated with diseases such as schizophrenia and autism spectrum 
disorder. Many brain areas, including the superior colliculus (SC), inferior colliculus 
(IC), mediodorsal thalamus (MD), basolateral amygdala (BLA), anterior cingulate cortex 
(ACC), and ventral hippocampus (VHPC), have been implicated in playing important 
roles in prepulse inhibition. While many studies have implicated GABA-A receptors in 
playing a role in PPI regulation, little work has been done on GABA-B receptors. An 
established rat model with induced prepulse inhibition impairment was used in this study.  
PPI impairment was induced via injection of the glutamate receptor antagonist 
dizocilpine. A subgroup of rats was also treated with the antihistamine pyrilamine to 
reverse the effects of dizocilpine.  
Objectives: The aims of this study are to: 1. Expand the understanding of prepulse 
inhibition in the context of neurological and developmental diseases such as autism 
spectrum disorder (ASD) and schizophrenia; 2. Identify potential significant differences 
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within GABA-B receptor densities in the rat SC, IC, MD, BLA, ACC, or VHPC between 
treatment groups with and without dizocilpine and groups with and without pyrilamine.  
Methods: Histological brain slides harvested from 36 Sprague-Dawley rats were 
provided by Dr. Edward Levin from Duke University’s Neurobehavioral Research Lab 
for this study. The brain slides were incubated in a radioligand solution specific for 
GABA-B receptors and exposed to autoradiograph film for approximately 12 weeks. The 
films were developed in a dark room and scanned electronically. GABA-B receptor 
densities were measured from the images and the data was analyzed using ANOVA and 
independent T tests.  
Results: ANOVA testing revealed significant differences between treatment groups in 
the MD and VHPC. However, only the MD was found to have significant GABA-B 
receptor differences when comparing the dizocilpine and pyrilamine treatment groups to 
the control group. The VHPC was found to have significant differences in GABA-B 
receptor densities when directly comparing the dizocilpine group to the pyrilamine 
treatment group, rather than to the control group. There were no significant differences in 
GABA-B receptor densities as a result of either dizocilpine or pyrilamine treatment in the 
SC, IC, BLA, ACC, or VHPC.  
Conclusion: Changes in GABA-B receptor levels appear to play a role in both the 
impairment and rescue of PPI in the rat MD. It does not appear to play a role in the SC, 
IC, BLA, ACC, or VHPC for either the impairment or rescue of PPI function.  
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INTRODUCTION 
 
Sensory Gating and Sensorimotor Gating 
 Sensory gating is a neurological process defined by the ability of the brain to filter 
out extraneous sensory stimuli in order to maintain manageable information flow and 
processing. For example, in a crowded noisy room, a person can focus on participating in 
a conversation without impedance from the surrounding ambient noise. The brain can 
effectively tone down other sounds in the room and improve attentional focus.  
One method of assessing sensory gating is P50 event-related potential (ERP) 
suppression. ERPs are electrophysiological responses to stimuli in the brain and are 
measured with electroencephalography (EEG) as voltage over time. P50 is a term used 
for an ERP that occurs 50 ms after a given stimulus, which is often an auditory click. 
While other types of stimuli, such as tactile and visual, can also be used to measure ERP 
suppression, acoustic stimuli are easier to regulate and deliver in a controlled 
environment. When a milder stimulus is introduced before the original stimulus, it 
normally produces a reduction in ERP amplitude due to sensory gating, and thus 
attenuating the response to a redundant stimulus.  
A similar phenomenon occurs with prepulse inhibition (PPI), the operational 
measure of sensorimotor gating. By providing a milder stimulus known as a prepulse 
before the introduction of a startling stimulus, or pulse, the subject will exhibit a reduced 
startle response to the second stimulus (Figure 1). The nervous system effectively 
manages to attenuate the strong startling stimulus as a consequence of the prepulse 
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stimulus. For example, a second stimulus given at an interstimulus interval (ISI) of 500 
ms after the first stimulus was shown to produce a 90% decrease in startle response 
(Adler et al., 1982). 
  
Figure 1. Schematic of Prepulse Inhibition. Figure 1A shows a pulse stimulus of a 
certain amplitude eliciting a startle response. Figure 1B demonstrates the effect of 
prepulse inhibition. When a milder prepulse is introduced before the same pulse stimulus, 
the startle response amplitude is attenuated.  
 
Although sensorimotor gating is often used interchangeably with sensory gating, 
these are two subtly different concepts (Brenner, Edwards, Carroll, Kieffaber, & Hetrick, 
2004). While the operational measure of sensory gating is P50 suppression, one can 
assess sensorimotor gating with PPI of acoustic startle response (ASR). The difference is 
that sensorimotor gating includes a motor component. ASR is measured with 
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electromyography (EMG) recordings rather than an EEG. During the EMG recording, the 
subject is placed in a sound attenuating chamber, and pure tone noises are introduced at 
varying decibels. Similar to measuring ERPs, the EMG startle response amplitudes can 
then be compared and analyzed. The focus of this thesis will be on sensorimotor gating, 
as it is more relevant to neurological and development disorders. 
 
The Role of Sensorimotor Gating in Neurological Diseases 
Currently, the pathophysiology of neurological and developmental disorders such 
as schizophrenia and autism spectrum disorder (ASD) are poorly understood. Due to their 
multifactorial nature, there is not one particular gene or faulty pathway responsible for 
each diseases’ phenotype. Rather, a combination of genetic and environmental factors 
come into play, with some contributing more than others. Ultimately, the overall lack of 
pathophysiological understanding makes it difficult to develop treatments for these 
diseases. While some drugs such as clozapine and risperidone have been shown to be 
effective in managing schizophrenia, there is scarce evidence for effective ASD treatment 
(Kane, Honigfeld, Singer, & Meltzer, 1988; Olivares et al., 2009). However, the 
neurological phenomena of sensorimotor gating and prepulse inhibition provide a 
potential model that can be used to gain a better understanding of these diseases.  
Deficits in PPI have been linked to psychiatric and developmental disorders such 
as schizophrenia and ASD. One study compared the prepulse inhibition of unmedicated 
schizophrenic patients to that of normal control patients (Adler et al., 1982). The PPI of 
control patients was found to have decreased their startle response by an average of 90% 
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at an ISI of 500 ms. However, the schizophrenic patients showed an average decrease of 
less than 15% in startle response at the same ISI. Numerous other studies have also 
supported not only the correlation between impaired prepulse inhibition with 
schizophrenia, but ASD as well (Bikovsky et al., 2016; Braff & Geyer, 1990; Haß, Bak, 
Szycik, Glenthøj, & Oranje, 2017). For instance, adults with ASD were shown to have 
significantly decreased PPI at an ISI of 60 ms compared to control participants (Perry, 
Minassian, Lopez, Maron, & Lincoln, 2007). By studying the mechanisms of PPI, one 
can potentially apply those findings towards further investigating the causes of 
schizophrenia and ASD.  
 
Animal Models 
A particularly effective and established animal model to study PPI is the Sprague 
Dawley rat with induced sensorimotor gating deficiencies (Mansbach & Geyer, 1989). 
Rats treated with a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, 
dizocilpine, have demonstrated a significant reduction of PPI. A subgroup of rats also 
received injections of pyrilamine, a histamine H1 receptor antagonist, to recover the PPI 
impairment. After performing neurobehavioral ASR assessments to confirm the desired 
effect on the rats, brain tissue obtained from these animals can be analyzed for potential 
differences in neurotransmitter receptor densities that may help elucidate the 
pathophysiology of sensorimotor gating deficiencies. Since this particular field has been 
relatively unexplored, few combinations of neurotransmitter receptors and brain regions 
have been analyzed for discrepancies that may be attributable to PPI impairment with this 
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animal model. For example, one autoradiographic study demonstrated that the gamma-
aminobutyric acid (GABA) receptor system activity was significantly reduced in 
hippocampal regions of autistic patients, while other neurotransmitter receptors such as 
serotonin, acetylcholine, and glutamate did not show any statistically significant 
discrepancies in the same region (Blatt et al., 2001). In this study, the aforementioned rat 
model was used to explore selected brain regions associated with PPI impairment for 
potential GABA receptor binding abnormalities.  
 
GABA 
GABA is an inhibitory neurotransmitter that plays various roles throughout the 
mammalian central nervous systems. It is mainly synthesized from glutamate by the 
enzyme glutamate decarboxylase in GABAergic neurons in the brain. The 
neurotransmitter has several different receptor subtypes (Enna & McCarson, 2013). Of 
these different variations, GABA-A and GABA-B are the primary subtypes of concern 
with regard to ligand binding autoradiography studies. GABA-A receptors are 
cholinergic and involve benzodiazepine and barbiturate receptor-linked chloride 
channels, while GABA-B receptors are metabotropic and involve GTP-binding protein 
and adenylate cyclase activity (Asano & Ogasawara, 1986; Guidotti, Corda, Wise, 
Vaccarino, & Costa, 1983; Wallner, Lindemeyer, & Olsen, 2018).  
Both GABA-A and GABA-B receptor pathways have been established to play 
integral roles in PPI regulation. It has been demonstrated that injection of picrotoxin, a 
GABA-A antagonist, into the central or medial ventral pallidum significantly reduced PPI 
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(Kodsi & Swerdlow, 1995). Mice with an α5(H105R) mutation that reduces expression of 
the α5 subunit of GABA-A receptors in the hippocampus have been reported to 
demonstrate attenuated PPI (Hauser et al., 2005). Injection of picrotoxin into the ventral 
hippocampus decreased PPI as well (Bast, Zhang, & Feldon, 2001). Several studies have 
also shown a significant reduction in PPI following injection of GABA-B antagonist 
phaclofen into the substantia nigra pars reticulata and nucleus reticularis pontis caudalis 
(Koch, Fendt, & Kretschmer, 2000; Yeomans et al., 2010).  Although both GABA-A and 
GABA-B seem to serve key roles in PPI regulation, GABA-B was selected for the 
purpose of this study since there has been less work done on role of GABA-B receptors 
in neurologic mechanisms than compared to GABA-A. This study aims to contribute 
results of GABA-B investigations to the larger existing body of existing work done on 
GABA-A.  
While there is strong evidence suggesting GABA-B is a key player in the 
modulation of PPI, the pathophysiology mechanisms of GABA-B are still rather poorly 
understood. There have been models proposed of PPI circuitry and studies measuring 
GABA-B levels in both humans with ASD and rat models, but there does not yet seem to 
be a general consensus. By conducting experiments to quantify GABA-B receptor 
densities in different areas of the rat model brain, one could potentially create a blueprint 
that may be used as a stepping stone to further the collective understanding of 
sensorimotor gating mechanisms and deficiencies.  
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Brain Regions 
It has been proposed that numerous brain regions play important roles in the 
regulation of PPI. Figure 2 shows a schematic of an auditory stimulus S being transmitted 
to different brain regions through the cochlea, and producing a startle response R. These 
areas are not an exhaustive list of brain regions implicated in PPI regulation, but 
summarize the key players with the most amounts of evidence. Of the many regions 
involved, the superior colliculus (SC), inferior colliculus (IC), mediodorsal thalamus 
(MD), basolateral amygdala (BLA), anterior cingulate cortex (ACC), and ventral 
hippocampus (VHPC) were selected as regions of interest for this study. While some of 
these regions, such as the SC, MD, and ACC, have already been implicated to regulate 
PPI via GABA-A mechanisms, there has been little work done on the involvement of 
GABA-B in these regions. Thus, this study aims to explore GABA-B receptor 
involvement in the SC, IC, MD, BLA, ACC, and VHPC with regards to PPI regulation.  
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Figure 2. Brain Regions Implicated in PPI Regulation in Rats. Shown above in the 
boxes are the proposed brain regions involved in regulating a startle response (R) 
produced by a stimulus (S). Aud – auditory cortex, BLA – basolateral amygdala, Coch – 
cochlea, IC – inferior colliculus, MPFC – medial prefrontal cortex, MS – medial septal 
nucleus, NAC – nucleus accumbens, HPC – hippocampus, MD – mediodorsal thalamus, 
PnC – nucleus reticularis pontis caudalis, PPTg – pedunculopontine nucleus, SC – 
superior colliculus, VP – ventral pallidum, VTA – ventral tegmental area (taken from 
Swerdlow, Geyer, & Braff, 2001). 
 
The SC is a major paired structure in the mammalian midbrain and is believed to 
play an important role in regulating spatial behavioral responses. It is divided into 
different layers, with the superficial layers receiving sensory information from the eye, 
and the deeper layers regulating eye movements. It has been shown that lesions of the 
superior colliculus in rat models show a decrease in the prepulse inhibition of ASR (M. 
Fendt, Koch, & Schnitzler, 1994). Injection of picrotoxin, a GABA-A inhibitor, into the 
rat model superior colliculus has demonstrated significantly enhanced PPI. This suggests 
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that GABA-A plays an important inhibitory role in the SC with regards to the 
sensorimotor gating deficient model (Markus Fendt, 1999).  
The IC is also a paired midbrain structure that serves very important auditory 
functions by receiving input from several peripheral brainstem nuclei and the auditory 
cortex. It is divided into three subdivisions: the central nucleus, a dorsal cortex, and an 
external cortex. GABAergic inhibition has been shown to play a vital role in regulating 
other neurons in the IC by exerting tonic control (Brandão, Anseloni, Pandóssio, De 
Araújo, & Castilho, 1999; Le Beau, Rees, & Malmierca, 1996). Lesions in the inferior 
colliculus of rat models have been shown to significantly decreased PPI as well (Li, 
Korngut, Frost, & Beninger, 1998).  
The MD is one of the largest nuclei of the thalamus. It has been suggested that the 
MD may play an important role in cognitive functions such as working memory and 
decision making (Bolkan et al., 2017; Chakraborty, Kolling, Walton, & Mitchell, 2016). 
There is significant interconnectivity between the MD and the prefrontal cortex in both 
rodents and monkeys (Groenewegen, 1988; Ray & Price, 1993; Xiao, Zikopoulos, & 
Barbas, 2009). MD lesions significantly reduced PPI, as did infusion of GABA-A agonist 
muscimol into the MD (Kodsi & Swerdlow, 1997).  
The BLA includes the basal, basolateral, and lateral nuclei of the amygdala, and 
receives sensory input from both cortical and subcortical structures (Campeau & Davis, 
1995). It has been suggested to play roles in fear-potentiated startle responses, fear 
conditioning, and startle conditioning, (Campeau & Davis, 1995; LeDoux, 2003). More 
significantly, the BLA has been implicated in contributing to PPI regulation. Neurotoxic 
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lesions of the BLA significantly reduced PPI and blocked fear-potentiated startle (Wan & 
Swerdlow, 1996). These mechanisms were found to be independent of dopamine 
mechanisms, since injection of the dopamine antagonist haloperidol did not reverse these 
effects.  
The ACC is a structure in the anteromedial aspect of the cerebral cortex and 
contains Brodmann areas 24, 32, and 33. It has been implicated in functions such as 
attention, working memory, cognition, emotion, and reward expectancy (Botvinick, 
Nystrom, Fissell, Carter, & Cohen, 1999; D’Esposito et al., 1995; MacDonald, 2000; 
Shidara, 2002). Upon examination of human ASD post mortem brains, both GABA-A 
and GABA-B receptors were found to be significantly decreased in the anterior cingulate 
cortex (A. Oblak, Gibbs, & Blatt, 2009; A. L. Oblak, Gibbs, & Blatt, 2010). It has been 
suggested that these GABA receptor discrepancies may play a role in the impaired social, 
emotional, and cognitive functions associated with ASD. 
The hippocampus is a major structure of the limbic system and is located inferior 
to the cerebral cortex. The VHPC has been implicated in functions such as social 
behavior, reward sensitivity, spatial awareness, working memory, and social memory (A. 
Becker, Grecksch, Bernstein, Höllt, & Bogerts, 1999, p. 1; Axel Becker & Grecksch, 
2000; Chambers, Moore, McEvoy, & Levin, 1996; Le Pen, Gaudet, Mortas, Mory, & 
Moreau, 2002). Neonatal lesions in the VHPC of rats were shown to induce post pubertal 
PPI deficits (Le Pen et al., 2003). Injection of the GABA-A antagonist picrotoxin into the 
VHPC of rats also decreased PPI, indicating a sensorimotor gating deficit (Bast et al., 
2001).  
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Autoradiography 
Autoradiography refers to the technique of capturing radioactivity decay emission 
patterns on x-ray film. By studying the films, one can determine relative radioactive 
intensities of areas exposed to film. There has already been significant work done 
outlining the regional activity of GABA-A and GABA-B throughout the rat model brain 
using autoradiography (Bowery, Hudson, & Price, 1987; Chu, Albin, Young, & Penney, 
1990). This is accomplished by selecting a radioactive ligand to specifically bind GABA-
A or GABA-B receptors. Once the ligand successfully binds to the target, it continues to 
decay, emitting radioactivity that can be captured and localized on film. Many studies use 
a radioligand containing the radioactive isotope tritium (3H) given its relatively lower 
levels of radiation compared to other isotopes. Thus, this approach was selected to 
evaluate GABA-B given its established efficacy.  
 
Specific Aims 
The purpose of this study is to investigate the regional densities of GABA-B 
receptors in brain regions of rat models with sensorimotor gating processing deficiency. 
By using autoradiography, the study will investigate any potential significant differences 
of GABA-B receptor densities in the SC, IC, MD, BLA, ACC, and VHPC of rat brains as 
a result of either dizocilpine or pyrilamine treatment. Using the resulting data, one could 
eventually compile a schematic profile describing the overall interactions and functions 
of GABA-B receptors with regard to PPI dysfunction. The investigation of the 
neuropathological mechanisms involved with PPI may ultimately aid in suggesting 
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avenues for further exploration that may contribute to developing more effective 
treatments and interventions for schizophrenia, ASD, and other neurodevelopmental 
disorders.  
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METHODS 
 
Animal Model 
  The histological brain slides used for this study were harvested from thirty-six 
adult female Sprague-Dawley rats (from Taconic Labs, Germantown, NY) and provided 
by Dr. Edward Levin of Duke University’s Neurobehavioral Research Lab. The rats were 
divided into 4 different treatment groups with 9 rats in each group. Rats in each group 
were further separated into temperature controlled vivariums that each housed 3 animals. 
The vivariums were regulated on an alternating 12-hour light and 12-hour dark cycle with 
ample food and water. Each group was treated with either sterile 0.9% saline solution 
(Hospira, Lake Forest, IL), pyrilamine (Sigma-Aldrich, St. Louis, MO), dizocilpine (MK-
801, Sigma-Aldrich, St. Louis, MO), or a combination of pyrilamine and dizocilpine. The 
dizocilpine was used to induce sensorimotor gating deficiency in the rat model. 
Pyrilamine has been found to successfully recover sensorimotor gating impairment, 
significantly improving PPI (Skefos et al., 2014). The compounds were administered via 
Azlet 2ML4 osmotic minipumps inserted between each rat’s scapulae (Durect, Cupertino, 
CA) for 4 weeks, at a rate of 0.15 mg dizocilpine/kg/day and 50 mg pyrilamine/kg/day.  
Testing of the rats’ ASR occurred every week during the dark phase. ASR and 
PPI were measured using the Med Associates Startle Reflex System (St. Albans, VT, 
USA). Each rat was placed in a sound attenuating chamber with a constant background 
white noise of 65 dB. Pure tone sounds were introduced through a speaker within the 
chamber at either 68, 71, or 77 dB at different prepulse-pulse intervals. The sound 
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intensities were calibrated using an Extech digital sound level meter before each testing 
session.  
After the behavioral analyses, the rats were anesthetized (100 mg Euthasol/kg, 
Virbac, Inc., Fort Worth, TX, USA) and sacrificed by exsanguination. The brains were 
immediately extracted and stored at -80°C. Histological slides were prepared at Duke 
University by slicing each brain into 20 μm coronal sections using a cryostat (Bright 
Instruments, Cambridgeshire, UK) and mounting the sections on slides treated with 0.5% 
gelatin and 0.05% chromium potassium sulfate (Superfrost Fisherbrand, Pittsburgh, PA).  
 
Autoradiography Experiments 
A buffer of 50 mM Tris-HCl with 2.25 mM CaCl2 was made and chilled 
overnight. The pH of the buffer was titrated to 7.2 on the following day. 36 μL of the 
GABA-B receptor antagonist [S-(R*,R*)]-[3-[[1-(3,4-Dichlorophenyl)ethyl]amino]-2-
hydroxypropyl](cyclohexylmethyl) phosphinic acid (CGP 54626 [3H]) radioligand 
(American Radiolabeled Chemicals, Saint Louis, MO) was then diluted in 600 mL of 
chilled buffer. Brain slides were selected from the -80°C freezer the day before the 
radioligand binding protocol was performed. For each experiment, 30 slides that 
contained the brain area of interest were selected, as well as a standard slide (Figure 3B) 
that contained a gradient of standard radioactivity values. Each slide contained 5 separate 
coronal brain slices from the same rat (Figure 3A). 3 slides were also randomly chosen 
for each experiment to serve as test slides, irrespective of the brain areas contained on the 
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slide. The test slides helped determine when the experimental film was ready to develop. 
The SC, IC, MD, BLA, ACC, and VHPC were all investigated in this study.  
 
Figure 3. Sample Brain and Standard Slide from MD Experiment Film. Figure 3A 
shows one single brain slide containing 5 coronal slices from the same rat. These slices 
contain the mediodorsal thalamus. Figure 3B shows the standard slide from the same film 
with 14 squares of increasing radioactivity, which were used to calibrate the density 
measurements (1 = least radioactive, 14 = most radioactive).  
 
The following radioligand binding protocol was carried out on trays of ice to limit 
nonspecific binding. All of the slides were pre-incubated in non-radioactive buffer for 1 
hour, and then incubated in the radioligand solution for 1 hour. After incubation, the 
slides were washed three times for 15 minutes each in chilled buffer, and then set to dry 
at room temperature. The batch of 30 experimental slides was then exposed to Kodak 
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Biomax MS films (Kodak, Rochester, NY) in a cassette for approximately 12 weeks. The 
3 test slides for each experiment were exposed to smaller pieces of film in one separate 
cassette. These served as controls to help determine when the experimental film was 
ready to develop. Each of the 3 test slide films were developed at approximately 11, 12, 
and 13 weeks after initial exposure to the films. The experimental film was only 
developed when one of the test films showed adequate levels of contrast that allowed 
proper GABA-B receptor binding visualization. Each film was developed using Kodak 
Developer and Rapid Fixer in a darkroom.  
The developed films were scanned with an Epson Perfection V750 Pro Scanner 
and analyzed using ImageJ software (Schneider, Rasband, & Eliceiri, 2012). The location 
of each brain region of interest was determined using a rat brain atlas with stereotaxic 
coordinates (Paxinos & Watson, 2007). Radioactivity values were first calibrated using 
the standard on each experimental film, which allowed the conversion of densitometric 
data to μCi/g tissue equivalents. Five measurements of the film density were sampled 
from the selected brain regions on each slide. The five values were then averaged, which 
produced a value that represented the mean GABA-B receptor density in the brain area of 
interest for one rat. The collective dataset of mean receptor densities was then used to run 
statistical tests.  
 
Statistical Analysis  
Analysis of variance (ANOVA) tests were first conducted for each dataset to 
assess if there were significant differences in GABA-B receptor densities between all 
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four different treatment groups. Independent sample t-tests were then performed to assess 
potential differences in GABA-B receptor binding densities between the control, 
dizocilpine, and pyrilamine treatment groups. Analyses were conducted to investigate the 
overall effects of dizocilpine and pyrilamine treatment by comparing the presence and 
absence of each respective treatment. The appropriate T test, either equal variances 
assumed or not assumed, was chosen for each group based on the results of Levene’s test 
for equality of variances. If Levene’s test was significant, the equal variances not 
assumed test was used. If Levene’s test was not significant, the equal variances assumed 
test was chosen. All statistical tests were two-sided and had an α value of 0.05. The 
analysis was carried out with SPSS Statistics Version 25 (IBM, Armonk, NY).  
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RESULTS 
Autoradiography Images   
 
Figure 4A. SC Autoradiography Scan. 
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Figure 4B. IC Autoradiography Scan. 
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Figure 4C. MD Autoradiography Scan. 
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Figure 4D. BLA Autoradiography Scan. 
 22 
 
Figure 4E. ACC Autoradiography Scan. 
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Figure 4F. VHPC Autoradiography Scan. 
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Shown above are selected autoradiography images scanned by an Epson 
Perfection V750 Pro Scanner. The locations of each brain region of interest are outlined 
as well. The films from each experiment seemed to develop with varying levels of 
darkness and contrast. For example, the background is lightest in the BLA scan (Figure 
4D), while there is significantly more background noise in the SC and MD scans (Figure 
4A, Figure 4C). The IC scan also had more prominent line patterns throughout the scan 
than the other images (Figure 4B). There may be several factors that contributed to these 
differences. For example, the manner in which each slide was fixed by the histologist 
may have varied. Although each film was exposed to radioactive slides for approximately 
12 weeks, the length of exposure varied by a few days for each of the experiments. This 
depended on when the spot films properly developed. Despite these variations between 
films, they should not have significantly affected analysis of GABA-B receptor densities 
on any one particular film since they were analyzed separately.  
 
Density Data 
The following tables list out the raw data GABA-B receptor density data collected 
from each experiment. Some datasets had noticeably higher density values (Table 6) 
compared to other brain regions, which may be indicative of higher inherent levels of 
GABA-B receptors in these regions rather than effects of drug treatment.    
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Table 1. Mean GABA-B Receptor Densities in the SC. The mean radioactivity 
densities are measured in μCi/g of tissue and are grouped into different treatment groups. 
The case number is an identifier for each brain slide.  
Case # Mean Dizocilpine Treatment Pyrilamine Treatment 
B2-1 96.108 - - 
B8-1 74.968 - - 
C1-1 105.247 - - 
C8-2 119.046 - - 
C6-2 123.947 - - 
C5-1 85.482 - - 
C3-1 87.081 - - 
C4-2 83.901 - - 
B6-2 96.265 - + 
B5-0 114.155 - + 
B8-2 109.111 - + 
B3-0 103.514 - + 
C4-1 66.357 - + 
C2-2 73.738 - + 
C7-0 114.111 - + 
B4-2 95.581 + - 
B1-2 98.245 + - 
B2-2 96.552 + - 
B7-2 102.629 + - 
B1-1 91.109 + - 
B4-0 103.526 + + 
B8-0 123.476 + + 
C8-1 108.439 + + 
C4-0 104.221 + + 
C3-2 102.273 + + 
C6-0 92.928 + + 
C3-0 99.497 + + 
B2-0 103.191 + + 
B3-1 101.421 + + 
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Table 2. Mean GABA-B Receptor Densities in the IC. The mean radioactivity 
densities are measured in μCi/g of tissue and are grouped into different treatment groups. 
The case number is an identifier for each brain slide. 
Case # Mean Dizocilpine Treatment Pyrilamine Treatment 
B2-1 78.766 - - 
B8-1 79.641 - - 
C1-1 90.708 - - 
C8-2 74.323 - - 
C6-2 67.818 - - 
C5-1 68.268 - - 
C3-1 71.953 - - 
C4-2 57.870 - - 
B6-2 87.705 - + 
B5-0 75.473 - + 
B8-2 70.506 - + 
B3-0 89.909 - + 
C4-1 80.211 - + 
C2-2 62.627 - + 
C7-0 74.087 - + 
C2-0 77.652 + - 
B4-2 68.969 + - 
B1-2 61.563 + - 
B2-2 65.520 + - 
B7-2 71.856 + - 
B1-1 70.865 + - 
B4-0 81.683 + + 
C8-1 94.089 + + 
C3-2 74.283 + + 
C6-0 79.404 + + 
B2-0 69.570 + + 
B3-1 79.844 + + 
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Table 3. Mean GABA-B Receptor Densities in the MD. The mean radioactivity 
densities are measured in μCi/g of tissue and are grouped into different treatment groups. 
The case number is an identifier for each brain slide. 
Case Mean Dizocilpine Treatment Pyrilamine Treatment 
B8-1 165.241 - - 
C1-1 339.688 - - 
C8-2 260.300 - - 
C6-2 280.421 - - 
C3-1 233.622 - - 
C4-2 229.495 - - 
B6-2 155.590 - + 
B5-0 203.708 - + 
B3-0 254.262 - + 
C7-2 232.968 - + 
C4-1 181.491 - + 
C2-2 151.931 - + 
C7-0 102.433 - + 
B4-2 440.683 + - 
B1-2 375.080 + - 
B2-2 438.748 + - 
B7-2 331.855 + - 
B1-1 255.431 + - 
B6-1 157.193 + + 
C8-1 209.244 + + 
C4-0 265.296 + + 
C3-2 253.926 + + 
C6-0 263.158 + + 
C3-0 369.010 + + 
B2-0 501.694 + + 
B3-1 428.404 + + 
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Table 4. Mean GABA-B Receptor Densities in the BLA. The mean radioactivity 
densities are measured in μCi/g of tissue and are grouped into different treatment groups. 
The case number is an identifier for each brain slide. 
Case # Mean Dizocilpine Treatment Pyrilamine Treatment 
B2-1 101.609 - - 
B8-1 191.556 - - 
C1-1 106.44 - - 
C3-1 110.124 - - 
C4-2 155.695 - - 
C5-1 199.926 - - 
C6-2 187.824 - - 
B3-0 147.283 - + 
B5-0 134.321 - + 
B6-2 116.105 - + 
B8-2 100.301 - + 
C2-2 212.979 - + 
C7-0 166.213 - + 
C7-2 154.689 - + 
B1-2 99.884 + - 
B2-2 127.456 + - 
B4-2 116.369 + - 
B7-2 153.462 + - 
C2-0 107.282 + - 
C4-1 113.206 + - 
B2-0 125.452 + + 
B3-1 94.541 + + 
B4-0 88.855 + + 
B6-1 112.46 + + 
B8-0 112.871 + + 
C3-0 130.596 + + 
C3-2 99.759 + + 
C4-0 162.027 + + 
C8-1 116.669 + + 
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Table 5. Mean GABA-B Receptor Densities in the ACC. The mean radioactivity 
densities are measured in μCi/g of tissue and are grouped into different treatment groups. 
The case number is an identifier for each brain slide. 
Case # Mean Dizocilpine Treatment Pyrilamine Treatment 
B2-1 103.020 - - 
B8-1 145.200 - - 
C1-1 150.119 - - 
C3-1 142.659 - - 
C4-2 144.139 - - 
C5-1 190.532 - - 
C6-2 107.003 - - 
C8-2 103.662 - - 
B3-0 84.251 - + 
B5-0 142.412 - + 
B6-2 98.754 - + 
B8-2 96.923 - + 
C2-2 140.455 - + 
C4-1 115.897 - + 
C7-0 152.997 - + 
B1-1 92.166 - + 
B1-2 173.188 + - 
B2-2 179.854 + - 
B4-2 133.276 + - 
B7-2 138.801 + - 
C2-0 130.266 + - 
C5-2 101.683 + - 
B2-0 98.910 + - 
B3-1 178.246 + - 
B4-0 154.203 + + 
B8-0 115.471 + + 
C3-0 106.237 + + 
C3-2 145.930 + + 
C6-0 155.647 + + 
C8-1 139.856 + + 
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Table 6. Mean GABA-B Receptor Densities in the VHPC. The mean radioactivity 
densities are measured in μCi/g of tissue and are grouped into different treatment groups. 
The case number is an identifier for each brain slide. 
Case # Mean Dizocilpine Treatment Pyrilamine Treatment 
B8-1 397.882 - - 
C1-1 360.989 - - 
C3-1 450.636 - - 
C4-2 424.798 - - 
C5-1 440.619 - - 
C6-2 464.249 - - 
C8-2 555.076 - - 
B3-0 411.979 - + 
B5-0 430.548 - + 
B6-2 372.425 - + 
B8-2 454.824 - + 
B2-2 394.725 - + 
B4-1 408.609 - + 
B7-0 417.553 - + 
B7-2 334.501 - + 
B1-1 529.377 + - 
B1-2 456.907 + - 
B2-2 463.755 + - 
B4-2 472.356 + - 
B7-2 512.243 + - 
C2-0 442.093 + - 
C5-2 521.172 + - 
B2-0 552.619 + + 
B3-1 452.163 + + 
B4-0 392.772 + + 
B8-0 363.931 + + 
C3-2 626.275 + + 
C6-0 520.034 + + 
C8-1 442.584 + + 
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Superior Colliculus 
 
Figure 5. Comparing GABA-B Receptor Densities in the SC. The mean radioactivity 
density of GABA-B receptors measured from each slide was plotted according to 
treatment groups of either saline control (n = 8), dizocilpine (n = 5), pyrilamine (n = 7), 
or both pyrilamine and dizocilpine (n = 9). The quartile values are shown by the boxes 
and the X represents the group mean.  
 
The ANOVA test did not show any significant difference between any of the 
treatment groups (p = 0.638). This is also rather apparent from looking at the close 
distribution of mean values for all four treatment groups (Figure 5). Levene’s test for 
equality of variances was significant (p = 0.016) comparing the dizocilpine group to the 
control group, and so the equal variances not assumed T test was chosen. Visually, one 
can see how the mean values were much more spread out for the control group than 
compared to the group treated with dizocilpine (Figure 5). Levene’s test was not 
significant (p = 0.828) when comparing the pyrilamine to saline control treatment group, 
thus the equal assumed test was chosen.  
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There was not a significant difference between either saline and dizocilpine (p = 
0.982) or saline and pyrilamine (p = 0.982) treatment groups by independent sample T 
test. This evidence suggests that changes in GABA-B receptor densities in the SC do not 
seem to play an important role in the induction of sensorimotor gating deficiency, or in 
the recovery of the impairment.  
 
Inferior Colliculus 
 
Figure 6. Comparing GABA-B Receptor Densities in the IC. The mean radioactivity 
density of GABA-B receptors measured from each slide was plotted according to 
treatment groups of either saline control (n = 8), dizocilpine (n = 6), pyrilamine (n = 7), 
or both pyrilamine and dizocilpine (n = 6). The quartile values are shown by the boxes 
and the X represents the group mean. 
 
The ANOVA test did not show any significant differences between treatment 
groups (p = 0.199). Levene’s test for equality of variances was not significant for either 
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the dizocilpine (p = 0.275) or pyrilamine (p = 0.923) treatment group comparisons. Thus, 
the equal variances not assumed T test was chosen for both analyses.  
While the overall means for the inferior colliculus were slightly lower than those 
found in the superior colliculus, there still was not a significant difference between the 
dizocilpine (p = 0.359) or pyrilamine (p = 0.491) treatment groups when compared to the 
control group. Changes in GABA-B receptor densities does not seem to play a significant 
role in the IC with regard to either the impairment or the recovery of sensorimotor gating.  
 
Mediodorsal Thalamus 
 
Figure 7. Comparing GABA-B Receptor Densities in the MD. The mean radioactivity 
density of GABA-B receptors measured from each slide was plotted according to 
treatment groups of either saline control (n = 6), dizocilpine (n = 5), pyrilamine (n = 7), 
or both pyrilamine and dizocilpine (n = 8). The quartile values are shown by the boxes 
and the X represents the group mean. 
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The ANOVA test showed significant differences between treatment groups (p = 
0.006). Levene’s test was not significant for either the dizocilpine comparison (p = 0.457) 
or the pyrilamine comparison (p = 0.929). Thus, the equal variances assumed test was 
chosen for both T tests.  
Independent T tests showed significant differences in GABA-B receptor densities 
for both the dizocilpine (p = 0.019) and the pyrilamine (p = 0.047) treated groups when 
compared to the control. This suggests that changes in GABA-B receptor densities play 
an important role in both the induction and rescue of sensorimotor gating deficiency in 
the rat model MD.  
Basolateral Amygdala 
 
Figure 8. Comparing GABA-B Receptor Densities in the BLA. The mean 
radioactivity density of GABA-B receptors measured from each slide was plotted 
according to treatment groups of either saline control (n = 7), dizocilpine (n = 6), 
pyrilamine (n = 7), or both pyrilamine and dizocilpine (n = 9). The quartile values are 
shown by the boxes and the X represents the group mean. 
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The ANOVA test did not reveal significantly different GABA-B receptor 
densities between treatment groups (p = 0.092). Levene’s test was significant for the 
dizocilpine comparison (p = 0.008) but was not significant for the pyrilamine comparison 
(p = 0.281). Thus, the equal variances assumed test was chosen for the pyrilamine 
comparison, and equal variances not assumed test was chosen for the dizocilpine 
comparison.  
Independent T tests did not show significant differences in GABA-B receptor 
densities for either the dizocilpine (p = 0.128) or the pyrilamine (p = 0.890) comparisons. 
This suggests that changes in GABA-B receptor densities do not play an important role in 
the BLA with regards to the induction or rescue of prepulse inhibition impairment in the 
rat model.  
Anterior Cingulate Cortex 
 
Figure 9. Comparing GABA-B Receptor Densities in the ACC. The mean 
radioactivity density of GABA-B receptors measured from each slide was plotted 
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according to treatment groups of either saline control (n = 8), dizocilpine (n = 8), 
pyrilamine (n = 8), or both pyrilamine and dizocilpine (n = 6). The quartile values are 
shown by the boxes and the X represents the group mean. 
 
 ANOVA test did not show significant differences between any of the treatment 
groups (p = 0.697). Levene’s test was not significant for either the dizocilpine (p = 0.866) 
or pyrilamine (p = 0.979) treatment comparisons, thus the equal variances assumed test 
was chosen for both analyses.  
 Neither the dizocilpine (p = 0.978) nor pyrilamine (p = 0.354) comparison 
independent T tests were significant. This suggests changes in GABA-B receptor 
densities do not play a role in the ACC with regards to the impairment and rescue of PPI.   
Ventral Hippocampus 
 
Figure 10. Comparing GABA-B Receptor Densities in the VHPC. The mean 
radioactivity density of GABA-B receptors measured from each slide was plotted 
according to treatment groups of either saline control (n = 7), dizocilpine (n = 7), 
pyrilamine (n = 8), or both pyrilamine and dizocilpine (n = 7). The quartile values are 
shown by the boxes and the X represents the group mean. 
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 ANOVA testing showed significant differences between treatment groups (p = 
0.050). Equal variances assumed independent sample T tests were chosen for both the 
dizocilpine and pyrilamine treatment group comparisons because both Levene’s tests 
were insignificant (p = 0.525 and p = 0.420 respectively).  
 Both T tests revealed no significant differences when comparing the dizocilpine 
(p = 0.127) or pyrilamine (p = 0.152) treatment groups to the control group. This suggests 
changes in GABA-B receptor densities do not play a significant role in either the 
impairment or rescue of PPI in the rat model VHPC. Upon conducting additional T tests 
between the different groups, it was found that there was a significant difference between 
the dizocilpine and pyrilamine groups (p = 0.001) themselves. This helps explain why the 
ANOVA test showed a significant difference between groups.   
 
Results Overview 
Table 7. Summary of Statistical Analysis. P values are shown for ANOVA, Levene’s 
test for equality of variances, and independent sample T tests, with an α value of 0.05. 
Significant ANOVA and T test p values are highlighted in yellow.  
  Pyrilamine Comparison Dizocilpine Comparison 
 
ANOVA 
Levene's 
Test 
Equal 
Variances 
T Test 
Levene's 
Test 
Equal 
Variances 
T Test 
SC 0.638 0.828 Assumed 0.982 0.016 Not Assumed 0.982 
IC 0.199 0.923 Assumed 0.491 0.275 Assumed 0.359 
MD 0.005 0.929 Assumed 0.047 0.457 Assumed 0.019 
BLA 0.092 0.281 Assumed 0.890 0.008 Not Assumed 0.128 
ACC 0.697 0.979 Assumed 0.354 0.866 Assumed 0.978 
VHPC 0.050 0.525 Assumed 0.127 0.420 Assumed 0.152 
 
 In summary, only the MD contained significant differences of GABA-B receptor 
densities when comparing the dizocilpine and pyrilamine treatment groups to the control 
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group. None of the other areas showed significant differences. The significant ANOVA 
test for the VHPC was likely due to differences between the dizocilpine and pyrilamine 
group rather than dizocilpine compared to the control and pyrilamine compared to the 
control.  
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DISCUSSION 
 
 Out of all six brain regions selected, only the MD was shown to have significant 
differences in GABA-B receptor densities between rats treated with pyrilamine and the 
control saline group. Pyrilamine is a known antihistamine that targets the histamine H1 
receptor and has been empirically shown to decrease H1 receptor binding in the rat model 
(Parsons & Ganellin, 2009; Skefos et al., 2014). Therefore, one would not expect it to 
affect GABA-B receptor levels. However, pyrilamine has been shown to interact with 
other receptors in the rat model, such as increasing nicotinic acetylcholine receptor 
binding. Perhaps there are unknown mechanisms that allow pyrilamine to affect the 
expression of GABA-B receptors in the MD. On the other hand, the data suggests that 
pyrilamine does not significantly affect GABA-B receptor densities in the rat SC, IC, 
BLA, ACC, or VHPC.  
The MD was also the only region shown to contain significant differences in 
GABA-B receptor levels between rats treated with and without dizocilpine. While 
dizocilpine is primarily an NMDA glutamate receptor antagonist, it has also been shown 
to inhibit nicotinic acetylcholine receptors, serotonin transporters, and dopamine 
transporters as well (Amador & Dani, 1991; Clarke & Reuben, 1995; Iravani, Muscat, & 
Kruk, 1999). In addition to these other neurotransmitters, these results suggest that 
dizocilpine may function in the rat MD partly through GABAergic mechanisms. 
Interestingly, injection of dizocilpine into the rat model MD has been very recently 
correlated with a reduction in extracellular MD GABA levels (Okada, Fukuyama, 
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Kawano, Shiroyama, & Ueda, 2019). This may be corroborated by the results from this 
study that show a significant increase in GABA-B receptor density as a result of systemic 
dizocilpine injection (Figure 7). Perhaps if GABA levels in the rat MD decrease due to 
local dizocilpine injection, GABA-B receptor expression is subsequently upregulated to 
compensate.  
Studies have shown that both induction of lesions on GABAergic interneurons 
and injection of the GABA-A receptor antagonist bicuculline methiodide into the BLA of 
rat models significantly decreases sociability (Paine, Swedlow, & Swetschinski, 2017; 
Truitt et al., 2007). These behaviors measured by social interaction and social preference 
tests are reflective of dysfunctional sociability as seen in patients with schizophrenia and 
ASD (American Psychiatric Association & American Psychiatric Association, 2013). The 
rat VHPC has also been shown to modulate social behavior by reciprocally 
communicating with the BLA (Felix-Ortiz & Tye, 2014). While the results of this study 
did not show significant differences of GABA-B receptor densities in either the BLA or 
VHPC due to dizocilpine or pyrilamine, it may be worthwhile repeating these 
experiments to investigate GABA-A instead. In addition to rat models, these regions have 
also been shown to play important roles in humans with ASD.  
Clinically, it has been demonstrated that the amygdala, thalamus, and 
hippocampus all seem to be implicated in the unique neuroanatomical features of patients 
with ASD. For example, patients with ASD were found to have reduced thalamic brain 
volumes compared to those of control groups, suggesting potential reductions in 
connectivity between cortical and subcortical structures (Tsatsanis et al., 2003). 
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Furthermore, the amygdala was found to be enlarged in children with ASD, while the 
hippocampus was significantly enlarged in both children and adolescents with ASD 
(Schumann, 2004). One should note, however, that these studies are not specific for the 
BLA, MD, and VHPC regions of each structure. Given the little clinical work done on 
these specific brain areas, it is difficult to confidently correlate the results of these studies 
with clinical implications of their functions in diseases such as ASD. Nevertheless, the 
discrepancy between the increase in amygdala and hippocampus volume and the decrease 
in thalamus volume may speak to the different roles these regions play in PPI regulation.  
Lesions in both the SC and IC have been shown to decrease PPI, providing strong 
evidence of their relevancy to sensorimotor gating (M. Fendt et al., 1994; Li et al., 1998). 
However, there has been very little work on the relevancy of GABA-B receptors to the 
SC and IC in the sensorimotor gating deficient brain. The data here suggests that there is 
no significant difference of GABA-B receptor densities in rat brains due to dizocilpine or 
pyrilamine injection. As it has already been demonstrated that injection of the GABA-A 
antagonist picrotoxin into the SC significantly increases PPI, it would be interesting to 
perform autoradiography experiments to corroborate the result. Further experiments 
could also be performed on the IC as well since there seems to be less existing evidence 
for the role of GABA-A receptors.  
Despite decreased levels of GABA-B receptors were found in the ACC of post 
mortem brains of humans with ASD, the results of this study revealed no significant 
GABA-B receptor density differences in the PPI impaired rat model compared to the 
control (A. L. Oblak et al., 2010). One possibility to consider is that the ACC may 
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contribute to ASD via non-PPI mechanisms, and that the ACC may not in fact be 
involved in PPI regulation. For example, the ACC may be more related to the socio-
emotional and facial processing aspects of ASD rather than sensorimotor gating (Grelotti, 
Gauthier, & Schultz, 2002; Joseph & Tanaka, 2003). However, further GABA-A 
experiments should be conducted on the ACC given the evidence of reduced GABA-A 
receptors in brains with ASD (A. Oblak et al., 2009). 
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LIMITATIONS 
 
One of the largest limitations of this study was the length of film exposure 
required by the experimental protocol. Each autoradiograph had to be exposed for about 
12 weeks, and if the developing process turned out defective, a new film would have to 
be re-developed for another 12 weeks. For example, upon developing the MD experiment 
it was discovered that the cassette somehow had leaked light onto the film (Figure 11). 
As a result, the contrast was inconsistent across the film and the experiment had to be 
repeated. The consideration of using Kodak Hyperfilm, which only takes 22 days to 
develop, instead of Kodak Biomax films may greatly benefit future experiments. 
Immunohistochemistry may also prove a much more efficient method for analyzing 
receptor densities.  
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Figure 11. Improper Autoradiograph Development of MD Slides. The black rectangle 
in the top left corner represents 1 brain slide with 5 coronal brain slices obtained from 1 
rat. Each autoradiograph contained 30 brain slides and 1 standard slide. The area 
highlighted in red shows an undeveloped portion of the autoradiograph, most likely due 
to light leakage. These brain slides were inviable due to the lack of contrast.  
 
Although 30 slides were selected for each experiment, not all of the slides were 
used for statistical analysis. After the films were developed there were some brains that 
were deemed inviable, either due to artefact, smudging of the brain, or inability to locate 
the brain region of interest. Figure 12A shows a perfect slide with all of the fixed brains 
intact. Several brains on slides were distorted, likely due to human mechanical error 
during the autoradiography experiment protocol. Since the brains are mounted on the 
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slides with gelatin, they are exposed to the open environment and easily susceptible to 
damage. However, some of these slides had a mixture of intact and smudged brains. For 
example, despite the two distorted brains on the right in Figure 12B, the SC was still 
identifiable in the first three brains sections from the left. However, there were also slides 
that were completely inviable because the brain regions were not identifiable with 
confidence. Figure 12C shows all five brains appearing rather hazy, perhaps from poor 
fixation or artefact caused during the autoradiography protocol. Only a few slides from 
each experiment were completely invalid, either due to inadequate visualization of the 
brain region or distortion of the brain.  
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Figure 12. SC Brain Slides. These are 3 of 30 slides sampled from the same developed 
SC film. The slides show an intact brain slide (A), a smeared slide that is still viable for 
analysis (B), and a completely inviable slide due to absence of the SC (C). 
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CONCLUSION 
 
Based on the results of this study, changes in GABA-B receptor levels seem to 
play a role in the impairment and rescue of PPI impairment only in the rat mediodorsal 
thalamus. There does not seem to be any significant differences in GABA-B receptor 
densities in the rat superior colliculus, inferior colliculus, basolateral amygdala, anterior 
cingulate cortex, or ventral hippocampus due to either systemic dizocilpine or pyrilamine 
injection. While the exact mechanisms of how dizocilpine and pyrilamine affect prepulse 
inhibition are poorly understood, this study implicates a degree of GABA-B receptor 
involvement in the MD of the rat model.  
The future goals of this study primarily involve replicating GABA-B receptor 
autoradiography experiments on the remaining brain regions that were proposed to be 
implicated in regulating PPI, such as the nucleus accumbens, pedunculopontine nucleus, 
and nucleus reticularis pontis caudalis (Swerdlow et al., 2001). Since there are two main 
subtypes of GABA receptors that differ in function and regulation of PPI, a potential 
future area of study would be to conduct experiments on the same brain regions for 
GABA-A receptors. This could potentially shine more light on the non-glutaminergic 
mechanisms dizocilpine acts by and the non-histaminergic mechanisms of pyrilamine in 
these regions.  
Once an adequate understanding of potential significant differences in GABA-A 
and GABA-B receptor levels throughout the implicated brain regions has been 
accomplished, other neurotransmitters may also be investigated. For instance, dopamine 
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and acetylcholine have also been shown to play important roles in regulating PPI in the 
rat model (Schreiber, Dalmus, & De Vry, 2002; Zhang, Forkstam, Engel, & Svensson, 
2000).  
Further investigations of the neurotransmitter mechanisms underlying PPI may 
help create new avenues for potential therapeutic research. For example, it has been 
found that the antipsychotic clozapine improves PPI in both rats administered with 
dizocilpine and human patients with schizophrenia (Kumari et al., 2007; Roegge, Perraut, 
Hao, & Levin, 2007). The previous neurobehavioral experiments conducted on the rat 
models used for this study suggested that chronic administration of pyrilamine reversed 
the dizocilpine-induced PPI impairment by a mechanism very similar to that of clozapine 
(Skefos et al., 2014). In addition to its histaminergic effects, clozapine is known to act on 
several other receptors as well, including dopamine, serotonin, norepinephrine, and 
acetylcholine (Coward, 1992). However, it is not yet known which mechanisms of 
clozapine help produce therapeutic effects, and which produce adverse side effects. 
Although clozapine does not act via GABAergic mechanisms, a better understanding of 
GABA’s role in PPI and sensorimotor gating may lead to further investigation of 
treatments for diseases such as ASD and schizophrenia.  
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